HOME >> BIOLOGY >> NEWS
Plague proteome reveals proteins linked to infection

RICHLAND, Wash. -- Recreating growth conditions in flea carriers and mammal hosts, Pacific Northwest National Laboratory scientists have uncovered 176 proteins and likely proteins in the plague-bacterium Yersinia pestis whose numbers rise and fall according to the diseases virulence.

The team, led by the Department of Energy laboratory staff scientists Mary Lipton and Kim Hixson, identified the proteins as unique biomarkers related specifically to growth condition, according to a study in the latest issue of the Journal of Proteome Research. Biomarkers associated with disease progression show promise as detection tools in public health and biodefense and can guide drug and vaccine designers in their quest to disrupt the microbes ability to infect.

Y. pestis is the bacterium that caused the infamous Black Death plagues. Fleas are vectors for the disease and can spread it to rodent and human hosts. This study mimicked environmental conditions of Y. pestis in flea and in mammalian systems.

The proteome is a survey of proteins in a cell. Lipton, Hixson and colleagues at the PNNL-based Environmental Molecular Sciences Laboratory and Lawrence Livermore National Laboratory used proteomic techniques called accurate mass and time tag mass spectrometry and clustering analysis to compare abundance changes in 992 proteins under four different growth conditions, at 26 degrees and 37 degrees Celsius and with and without calcium.

They found 89 candidate proteins with similar abundance changes to 29 known virulence-linked proteins, and an additional 87 disease-condition-associated hypothetical proteins. The Institute for Genomic Research defines a hypothetical protein as one identified by a gene-finding algorithm that matches no other known protein sequence or contains no other evidence that it is an actual product of a gene.

The study authors said the same approach is being applied to a search for biomarkers across a wide r
'"/>

Contact: Bill Cannon
cannon@pnl.gov
509-375-3732
DOE/Pacific Northwest National Laboratory
22-Nov-2006


Page: 1 2

Related biology news :

1. A wolf in sheeps clothing: Plague bacteria reveal one of their virulence tricks
2. Plague agent helps UT Southwestern researchers find novel signaling system in cells
3. Protein structures for the entire yeast proteome
4. MicroRNAs, alternative splicing and the muscle proteome
5. Sperm proteome gives tantalizing glimpse towards the origin of sex
6. Scientists characterize proteome of human cornea
7. Satellite tracking reveals threats to Borneo pygmy elephants
8. New technology reveals seal behavior
9. Innovative research technique reveals another natural wonder in Yellowstone Park
10. Mathematics reveals genetic pattern of tumor growth
11. CU study reveals why starling females cheat

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Plague proteome reveals proteins linked infection

(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/26/2015)... -- The Granite Club, Canada,s ... today announced it has implemented a state-of-the-art access and ... members and staff, while restricting access to authorized users ... FST,s IMID Access system because it has the perfect ... staff, in addition to unparalleled security," said James ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
(Date:4/16/2015)... Washington (PRWEB) April 16, 2015 ... Applied Cancer Science and Resolution Bioscience, Inc. today ... to co-develop a novel, blood-based, clinic ready, Next ... cancer (NSCLC). The collaboration is the first to ... RET, and ROS1 fusions in blinded plasma samples ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
Cached News: